Antibiotice SAATB:BUH

0.582
0.002 / 0.34%
32.50k
24.09%
0.5902
Close in RONToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Oct 01 2014 15:28 BST.

About the company

324.91m17.50m19911.44k
Revenue in RON (TTM)Net income in RONIncorporatedEmployees
IndustryPharmaceuticals & BiotechnologyLocation
Antibiotice SA
str. Valea Lupului nr.1
IASI707410
Romania
ROU
Phone+40 232209583Fax+40 232209633Websitehttp://www.antibiotice.ro
Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.

Mergers & acquisitions

There are no recent mergers or acquisitions for Antibiotice SA.
Data delayed at least 15 minutes, as of Oct 01 2014 15:28 BST.

Peer analysis

Company Revenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings
(TTM)
Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excluding
extraordinary items (TTM)
EPS (including
extraordinary items) (TTM)
Revenue per
share (TTM)
Book value per
share (MRQ)
Asset turnover
(TTM)
Inventory turnover
(TTM)
Receivables turnover
(TTM)
Revenues per
employee (TTM)
Return on
average
assets
(TTM)
Return on
average
assets
(5 yr average)
Return on
investment
(TTM)
Return on
investment
(5 yr average)
Gross margin (TTM)Gross margin (5 yr average)Net profit margin (TTM)Net Profit margin (5 Yr Average)Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio (5 yr average)Revenue
(Year-over-year change%)
Revenue
(5 yr growth rate)
Net income
(Year-over-year change%)
Net income
(5 Yr growth rate)
Capital
expenditure
(5 Yr growth rate)
Dividend
(5 yr growth rate)
ReNeuron Group Plc
124.38k-39.95m353.96m27--2.88--2,845.86-0.0052-0.00520.000.01210.0015--0.0433814.81-46.5772-73.7792-52.0688-73.7792-----32,118.18-22,761.15----0.0001--29.41-25.0472-11.3633--34.01--
Scancell Holdings Plc
0-12.57m387.89m7--7.56-----0.0103-0.01030.000.04040.00----0.00-29.5957-31.5627-31.3768-31.5627------------0.00-------16.878---0.3879--
Neovacs SA
193.52k-30.28m325.75m20------1,683.23-0.3493-0.34930.0022-------------------5,121.271---15,647.23-23,561.37---149.357-----61.8174-5.45963.92------
Proteome Sciences plc
12.08m-17.80m432.73m33------35.82-0.0162-0.01620.011-0.01120.30511.612.3464,748.18-44.9716------72.2672.48-147.385-69.28920.1533-15.07741.38--85.3220.2725.96---21.5695--
e-Therapeutics plc
0-38.94m433.36m21--1.89-----0.0261-0.02610.000.15350.00----0.00-15.3786-31.2799-15.6761-31.2799------------0.00-------20.608--14.08--
Abzena PLC
----446.16m86-------------------------------------------------3.1018---2,385.35------
Haemato AG
989.36m44.66m376.39m187.901.509.350.38040.52050.520511.462.742.346.7130.03--9.888.4913.358.497.819.414.236.700.72128.420.357378.60422.9663.4016.1414.79----
Genticel SA
----390.72m30-----------------------------------------------------5.457------
Tigenix NV
12.49m-65.06m401.73m56------32.16-0.0573-0.0734----------50,607.14---34.7641---34.764152.5172.48-520.9598-750.5365---28.6172----5.3168.047.41---26.7099--
Biotie Therapies Oyj
77.23m-23.37m434.13m37--1.21--5.62-0.0117-0.01170.03870.17830.1449--9.42473,622-4.3838-20.8282-4.4943-20.8282-----30.2614-175.0356----0.2062--473.6340.14124.51--89.37--
Antibiotice SA
324.91m17.50m389.38m1.44k22.621.1410.801.200.02560.02560.4840.50940.64451.561.30--3.475.765.245.7671.2071.655.396.201.452.060.221333.426.497.4134.24-3.5339-4.561314.74
BIOTON SA
349.29m-6.57m447.38m1.03k--0.324234.191.28-0.073-0.0733.8715.210.17122.322.51322,125-0.3231-8.1863-0.4183-8.186344.0346.00-1.8874-33.5910.9224--0.1303---16.23053.01-125.9956---20.7882--
Hansa Medical AB
1.99m-9.56m333.62m10--9.75--167.72-0.8128-0.81280.16942.730.0618--2.58514,040-29.7012-45.2162-31.5435-45.2162100.00126.65-480.7583-713.0685---584.44030.00---34.05475.41-6.6559------
Kancera AB
979.49k-5.94m347.97m7--25.09--355.26-0.3864-0.38640.04940.2910.0857--6.12---51.9457---59.9746--68.59---606.4691-----298.58540.1298------68.44------
Data as of Oct 01 2014. Currency figures normalised to Antibiotice SA's reporting currency: .
Data delayed at least 20 minutes, as of Oct 02 2014 00:41 BST.

Institutional shareholders

HolderShares% Held
Oltenia SIF SA (Investment Management)
as of 31 Oct 2013
76.34m10.83%
Transilvania SIF SA (Invt Mgmt)
as of 30 Sep 2013
22.92m3.25%
Banat-Crisana SIF SA (Investment Management)
as of 30 Sep 2013
11.56m1.64%
St. Galler Kantonalbank AG (Private Banking)
as of 31 May 2014
5.73m0.81%
Parametric Portfolio Associates LLC
as of 31 Jul 2014
3.57m0.51%
Polunin Capital Partners Ltd.
as of 31 Aug 2013
3.55m0.50%
Financial Investment Company Moldova SA (Invt Mgmt)
as of 30 Jun 2014
3.32m0.47%
Danske Bank A/S (Investment Management)
as of 31 Aug 2014
1.98m0.28%
Zepter SAI SA
as of 31 Dec 2013
1.55m0.22%
BT Asset Management SAI SA
as of 30 Jun 2014
1.24m0.18%
18.69%
Per cent of shares
held by top holders
Data from 28 Jun 2013 - 31 Aug 2014Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.